Correction: COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants

WHO

Following publication of the original article [1], the authors identified an error in Tables 1 and 2.
The correct Table 1 is given in this correction.
In Table 2, the data for Duration of vasopressors, days under the heading of variable has been corrected in this correction and the complete Table 2 is given in this correction.
The correct Table 2 is given in this correction.
In this article, the legend for Fig. 3 was incorrectly published.
Incorrect legend of Fig. 3: Fig. 3 Unsupervised analysis of the clinical and biological characteristics of the by self-organized maps (SOMs).Unsupervised analysis by SOM automatically located patients with similar clinical and paraclinical parameters within 1 of 40 small groupings ("districts") throughout the map.The more similar the patients, the closer on the map.Each individual map shows the mean values or proportions per district for each characteristic: blue indicates the lowest average values, red the highest, with numbers shown for a selection of representative districts in each SOM.For instance, immunosuppressed patients were more frequently located in the upper districts and also had higher serum urea levels, less frequent Delta variant infection, higher SAPS II and SOFA scores and  instance, immunosuppressed patients were more frequently located in the upper districts and also had higher serum urea levels, less frequent Delta variant infection, higher SAPS II and SOFA scores and day-28 mortality rates.WHO World Health Organization, SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology Score II, MV mechanical ventilation The original article has been corrected.

Table 1
Patient's characteristics at the time of their admission to the intensive care unit according to the CAPA

status Variable n/n a All patients, n = 566 Non-CAPA patients, n = 537 CAPA patients, n = 29 p
The more similar the patients, the closer on the map.Each individual map shows the mean values or proportions per district for each characteristic: blue indicates the lowest average values, red the highest, with numbers shown for a selection of representative districts in each SOM.For

Table 1 (
continued)Results are N (%), means (± standard deviation) or medians (interquartile range, i.e., quartile 1; quartile 3) CAPA COVID-19-associated pulmonary aspergillosis, ICU intensive care unit, Ct cycle threshold, WHO World Health Organization, SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology Score II, NIV non-invasive ventilation, C-PAP continuous-positive airway pressure, MV mechanical ventilation, ECMO extracorporeal mechanical ventilation Two-tailed p-values come from unadjusted comparisons using Chi-square or Fisher's exact tests for categorical variables, and t-tests or Mann-Whitney tests for continuous variables, as appropriate.No adjustment for multiple comparisons was performed.Bolded p-values are significant at the p < 0.05 level a Numbers of non-CAPA/CAPA patients data available b Includes HIV infection, long-term corticosteroid treatment, and other immunosuppressive treatments c Defined as < 30 Binding Antibody Units (BAU)/mL

Table 2
Management and outcomes of patients with severe SARS-CoV-2 infection during their intensive care unit stay according to the CAPA status Results are N (%), means (± standard deviation) or medians (interquartile range, i.e., quartile 1; quartile 3) CAPA COVID-19-associated pulmonary aspergillosis, MV mechanical ventilation, ECMO extracorporeal membrane oxygenation, VAP ventilator-acquired pneumonia, IMV invasive mechanical ventilation Two-tailed p-values come from unadjusted comparisons using Chi-square or Fisher's exact tests for categorical variables, and t-tests or Mann-Whitney tests for continuous variables, as appropriate.No adjustment for multiple comparisons was performed.Bolded p-values are significant at the p < 0.05 level a Numbers of non-CAPA/CAPA patients data available b VAP episodes were recorded per definition in patients under IMV since more than 48 h